Agile Therapeutics (NASDAQ:AGRX) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Agile Therapeutics (NASDAQ:AGRX) in a research note published on Wednesday morning. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.

Separately, Maxim Group restated a hold rating on shares of Agile Therapeutics in a research note on Monday, March 18th.

Agile Therapeutics Price Performance

NASDAQ:AGRX opened at $0.37 on Wednesday. Agile Therapeutics has a 12 month low of $0.20 and a 12 month high of $4.06. The firm has a market cap of $2.57 million, a price-to-earnings ratio of -0.10 and a beta of 1.25. The company’s 50 day moving average is $0.39 and its 200-day moving average is $1.18.

Agile Therapeutics (NASDAQ:AGRX) last announced its earnings results on Wednesday, May 15th. The specialty pharmaceutical company reported ($0.63) earnings per share (EPS) for the quarter. The company had revenue of $5.72 million for the quarter.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Agile Therapeutics stock. Armistice Capital LLC lifted its holdings in Agile Therapeutics, Inc. (NASDAQ:AGRX) by 10.2% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 108,000 shares of the specialty pharmaceutical company’s stock after buying an additional 10,000 shares during the quarter. Armistice Capital LLC owned about 3.65% of Agile Therapeutics worth $211,000 at the end of the most recent quarter. 10.92% of the stock is currently owned by institutional investors and hedge funds.

Agile Therapeutics Company Profile

Agile Therapeutics, Inc, a women's healthcare company, engages in the research, development, and commercialization of prescription contraceptive products for women in the United States. It offers Twirla, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.